Tyra Biosciences, Inc.
TYRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001863127
In the last 90 days, Tyra Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 168 institutions reported holding it in 13F filings for Q2 2026, worth $2.22B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Tyra Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $20.0K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$20.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Tyra Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Harris Todd | President and CEO | 1,438,495 | Sep 17, 2026 | 3 |
| Rueb Yuliya | Vice President, Finance (PAO) | 11,258 | Sep 17, 2026 | 2 |
| Fuhrman Alan | Chief Financial Officer | 37,115 | Sep 17, 2026 | 3 |
| RA Capital Healthcare Fund LP | Director, 10% Owner | 10,259,291Indirect | Sep 17, 2026 | 2 |
| Ra Capital Management, L.P. | Director, 10% Owner | 10,259,291Indirect | Sep 17, 2026 | 2 |
| Kolchinsky Peter | Director, 10% Owner | 10,259,291Indirect | Sep 17, 2026 | 2 |
| Shah Rajeev M. | Director, 10% Owner | 10,259,291Indirect | Sep 17, 2026 | 2 |
| RA Capital Nexus Fund, L.P. | Director | 10,259,291Indirect | Sep 17, 2026 | 2 |
| Verjee Rehan | Director | 972 | Sep 11, 2026 | 2 |
| More Robert J | Director | 3,823,425Indirect | Jun 1, 2026 | 3 |
| Gulfo Adele M. | Director | – | Jun 1, 2026 | 1 |
| Moran Susan | Director | – | Jun 1, 2026 | 1 |
| Simson Jake | Director | – | Jun 1, 2026 | 1 |
| Rothenberg Stephen Michael | Director | – | Jun 1, 2026 | 1 |
| Ashar Bhavesh | Chief Operating Officer | 15,013 | May 7, 2026 | 2 |
| Warner Douglas J | Chief Medical Officer | 25,000 | May 7, 2026 | 1 |
| Dable Habib J | Director | – | Apr 20, 2026 | 1 |
| Kaplan Gilla | Director | 28,231 | Mar 27, 2026 | 1 |
| Bensen Daniel | Chief Discovery Officer | 146,981 | Feb 13, 2026 | 5 |
| Kjellson Nina S | Director | 443,885Indirect | Feb 7, 2025 | 0 |
| Boxer Capital Management, LLC | Other: See remarks | 4,448,359Indirect | Oct 22, 2024 | 0 |
| Subramony Siddarth | Director, 10% Owner | – | May 31, 2024 | 0 |
| Tada Hiroomi | Chief Medical Officer | 86,435 | Mar 19, 2024 | 0 |
| Lewis Joseph | Other: See Remarks | 85,939Indirect | Feb 8, 2024 | 0 |
| Boxer Asset Management Inc. | Other: See Remarks | 85,939Indirect | Feb 8, 2024 | 0 |
| Boxer Capital, LLC | Other: See Remarks | 85,939Indirect | Feb 8, 2024 | 0 |
| Davis Aaron I. | Other: See Remarks | 85,939Indirect | Feb 8, 2024 | 0 |
| MVA Investors, LLC | Other: See Remarks | 85,939Indirect | Feb 8, 2024 | 0 |
| Chen Isan | Director | 192,783 | Jun 2, 2023 | 0 |
| Patel Piyush R. | Chief Development Officer | 73,794 | Feb 23, 2023 | 0 |
| van den Boom Esther | Chief Financial Officer | 121,897 | Sep 19, 2022 | 0 |
| Hudkins Robert L. | Chief Technology Officer | 273,576 | Sep 19, 2022 | 0 |
| Swanson Ronald V. | Chief Scientific Officer | 273,254 | Sep 8, 2022 | 0 |
| Fawaz Ali D. | General Counsel and Secretary | – | May 16, 2022 | 0 |
| Cormorant Asset Management, LP | Other: Former 10% Owner | 1,069,932Indirect | Sep 21, 2021 | 0 |
| Chen Bihua | Director, Other: Former 10% Owner | 1,069,932Indirect | Sep 21, 2021 | 0 |
| Cormorant Global Healthcare Master Fund, LP | Other: Former 10% Owner | 1,069,932Indirect | Sep 21, 2021 | 0 |
| Cormorant Private Healthcare Fund III LP | Other: Former 10% Owner | 1,069,932Indirect | Sep 21, 2021 | 0 |
| Canaan XI L.P. | 10% Owner | 473,396 | Sep 20, 2021 | 0 |
| Canaan Partners XI LLC | 10% Owner | 473,396 | Sep 20, 2021 | 0 |
| Canaan Partners 2020+ Co-Investment LLC | 10% Owner | 473,396 | Sep 20, 2021 | 0 |
| Canaan 2020+ Co-Investment L.P. Series 7 | 10% Owner | 473,396 | Sep 20, 2021 | 0 |
| Janney Daniel | 10% Owner | 4,080,296Indirect | Sep 17, 2021 | 0 |
| Hudson Peter A | 10% Owner | 4,080,296Indirect | Sep 17, 2021 | 0 |
| Alta Partners NextGen Fund II, L.P. | 10% Owner | 4,080,296Indirect | Sep 17, 2021 | 0 |
| Alta Partners NextGen Fund II Management, LLC | 10% Owner | 4,080,296Indirect | Sep 17, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2025 (view filing)8:06 PM ET | Jun 12-16 | 4 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +163.3K | $10.19 | +$1.66M | +1.6%10.3M after | 3 lots |
| Jun 20, 2025 (view filing) | Jun 17-18 | 3 days | Kaplan GillaDirector | SSale | −9.58K | $9.78 | −$93.7K | −25.3%28.2K after | 2 lots |
| Nov 17, 2025 (view filing) | Nov 13-17 | 4 days | Bensen DanielChief Operating Officer | SSale | −131.4K | $16.04 | −$2.11M | −30.7%296.6K after | 4 lots10b5-1 |
| Nov 19, 2025 (view filing) | Nov 18-19 | 1 day | Bensen DanielChief Operating Officer | SSale | −125.6K | $16.17 | −$2.03M | −42.3%171.0K after | 2 lots10b5-1 |
| Nov 25, 2025 (view filing) | Nov 21 | 4 days | More Robert JDirector | SSale | −246.9K | $20.25 | −$5.00M | −6.1%3.83M after | 10b5-1 |
| Dec 16, 2025 (view filing) | Dec 12 | 4 days | Bensen DanielChief Discovery Officer | SSale | −8.00K | $22.64 | −$181.1K | −4.7%163.0K after | 10b5-1 |
| Dec 19, 2025 (view filing) | Dec 19 | Same day | More Robert JDirector | SSale | −10.0K | $25.00 | −$250.0K | −0.3%3.82M after | 10b5-1 |
| Jan 20, 2026 (view filing) | Jan 12 | 8 daysLate | Bensen DanielChief Discovery Officer | SSale | −8.00K | $28.52 | −$228.2K | −4.9%155.0K after | 2 lots10b5-1 |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Bensen DanielChief Discovery Officer | SSale | −8.00K | $32.87 | −$263.0K | −5.2%147.0K after | 2 lots10b5-1 |
| Mar 27, 2026 (view filing) | Mar 25 | 2 days | Kaplan GillaDirector | SSale | −14.3K | $36.97 | −$528.5K | −33.6%28.2K after | |
| Sep 11, 2026 (view filing)4:30 PM ET | Sep 9 | 2 days | Verjee RehanDirector | PPurchase | +971.89 | $20.58 | +$20.0K | New position971.89 after | |
| Sep 17, 2026 (view filing)4:31 PM ET | Sep 15 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +9.08M | $22.03 | +$200.0M | –11.6M after | Derivative |